Terms: = Leukemia AND SERPINE1, PAI, PAI-1, PAI1, PLANH1 AND Treatment
38 results:
1. Pharmacotherapeutic advances for chronic myelogenous leukemia: beyond tyrosine kinase inhibitors.
Costa A; Scalzulli E; Carmosino I; Ielo C; Bisegna ML; Martelli M; Breccia M
Expert Opin Pharmacother; 2024 Feb; 25(2):189-202. PubMed ID: 38488824
[TBL] [Abstract] [Full Text] [Related]
2. miR-181a plays the tumor-suppressor role in chronic myeloid leukemia CD34
Zhang X; Ma W; Xue W; Wang Y; Chen P; Li Q; Li YY; Hu X; Zhao Y; Zhou H
Cell Mol Life Sci; 2023 Dec; 81(1):10. PubMed ID: 38103082
[TBL] [Abstract] [Full Text] [Related]
3. Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: laboratory tools for an early and differential diagnosis.
Moreno-Castaño AB; Fernández S; Ventosa H; Palomo M; Martinez-Sanchez J; Ramos A; Ortiz-Maldonado V; Delgado J; Fernández de Larrea C; Urbano-Ispizua A; Penack O; Nicolás JM; Téllez A; Escolar G; Carreras E; Fernández-Avilés F; Castro P; Diaz-Ricart M
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37045474
[TBL] [Abstract] [Full Text] [Related]
4. Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TM5614 combined with a tyrosine kinase inhibitor.
Takahashi N; Kameoka Y; Onizuka M; Onishi Y; Takahashi F; Dan T; Miyata T; Ando K; Harigae H
Cancer Med; 2023 Feb; 12(4):4250-4258. PubMed ID: 36151699
[TBL] [Abstract] [Full Text] [Related]
5. TM5614, an Inhibitor of Plasminogen Activator Inhibitor-1, Exerts an Antitumor Effect on Chronic Myeloid leukemia.
Sasaki K; Fujiwara T; Ochi T; Ono K; Kato H; Onodera K; Ichikawa S; Fukuhara N; Onishi Y; Yokoyama H; Miyata T; Harigae H
Tohoku J Exp Med; 2022 Jun; 257(3):211-224. PubMed ID: 35491124
[TBL] [Abstract] [Full Text] [Related]
6. Biomarkers of Glucose Metabolism Alterations and the Onset of Metabolic Syndrome in Survivors of Childhood Acute Lymphoblastic leukemia.
Konończuk K; Muszyńska-Rosłan K; Konstantynowicz-Nowicka K; Krawczuk-Rybak M; Chabowski A; Latoch E
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409072
[TBL] [Abstract] [Full Text] [Related]
7. Targeting of plasminogen activator inhibitor-1 activity promotes elimination of chronic myeloid leukemia stem cells.
Yahata T; Ibrahim AA; Hirano KI; Muguruma Y; Naka K; Hozumi K; Vaughan DE; Miyata T; Ando K
Haematologica; 2021 Feb; 106(2):483-494. PubMed ID: 32001531
[TBL] [Abstract] [Full Text] [Related]
8. The regulation of inflammation-related genes after palmitic acid and DHA treatments is not mediated by DNA methylation.
Samblas M; Carraro JC; Martínez JA; Milagro FI
J Physiol Biochem; 2019 Aug; 75(3):341-349. PubMed ID: 31423543
[TBL] [Abstract] [Full Text] [Related]
9. Endothelial Function in Children with Acute Lymphoblastic leukemia (ALL) May Reflect the Clinical Outcome.
Doroszko A; Niedzielska E; Jakubowski M; Porwolik J; Turek-Jakubowska A; Szahidewicz-Krupska E; Sieczkowski B; Dobrowolski P; Radziwon A; Skomro R; Derkacz A; Mazur G; Chybicka A; Szuba A
Biomed Res Int; 2018; 2018():7918091. PubMed ID: 30534565
[TBL] [Abstract] [Full Text] [Related]
10. Characteristics of fibrinolytic disorders in acute promyelocytic leukemia.
Wang P; Zhang Y; Yang H; Hou W; Jin B; Hou J; Li H; Zhao H; Zhou J
Hematology; 2018 Dec; 23(10):756-764. PubMed ID: 29724147
[TBL] [Abstract] [Full Text] [Related]
11. Venoocclusive disease due to chemotherapy for pediatric acute lymphoblastic leukemia is associated with increased levels of plasminogen-activator inhibitor-1.
Mauro M; Saggiorato G; Sartori MT; Gallo G; De Bortoli M; Bonetti E; Zaccaron A; Vitale V; Balter R; Chinello M; Cesaro S
Pediatr Blood Cancer; 2018 Jun; 65(6):e26963. PubMed ID: 29350496
[TBL] [Abstract] [Full Text] [Related]
12. Coagulation profile during induction chemotherapy in childhood acute lymphoblastic leukemia.
Sehgal S; Sharma S; Chandra J; Nangia A
Indian J Pathol Microbiol; 2017; 60(1):50-56. PubMed ID: 28195091
[TBL] [Abstract] [Full Text] [Related]
13. Arsenic trioxide inhibits transforming growth factor-β1-induced fibroblast to myofibroblast differentiation in vitro and bleomycin induced lung fibrosis in vivo.
Luo F; Zhuang Y; Sides MD; Sanchez CG; Shan B; White ES; Lasky JA
Respir Res; 2014 Apr; 15(1):51. PubMed ID: 24762191
[TBL] [Abstract] [Full Text] [Related]
14. Gene expression analysis in radiotherapy patients and C57BL/6 mice as a measure of exposure to ionizing radiation.
Filiano AN; Fathallah-Shaykh HM; Fiveash J; Gage J; Cantor A; Kharbanda S; Johnson MR
Radiat Res; 2011 Jul; 176(1):49-61. PubMed ID: 21361780
[TBL] [Abstract] [Full Text] [Related]
15. Involvement of RAGE, NADPH oxidase, and Ras/Raf-1 pathway in glycated LDL-induced expression of heat shock factor-1 and plasminogen activator inhibitor-1 in vascular endothelial cells.
Sangle GV; Zhao R; Mizuno TM; Shen GX
Endocrinology; 2010 Sep; 151(9):4455-66. PubMed ID: 20630999
[TBL] [Abstract] [Full Text] [Related]
16. Physical activity and fitness in adolescent and young adult long-term survivors of childhood acute lymphoblastic leukaemia.
Järvelä LS; Niinikoski H; Lähteenmäki PM; Heinonen OJ; Kapanen J; Arola M; Kemppainen J
J Cancer Surviv; 2010 Dec; 4(4):339-45. PubMed ID: 20552291
[TBL] [Abstract] [Full Text] [Related]
17. Downregulation of ZEB1 and overexpression of Smad7 contribute to resistance to TGF-beta1-mediated growth suppression in adult T-cell leukemia/lymphoma.
Nakahata S; Yamazaki S; Nakauchi H; Morishita K
Oncogene; 2010 Jul; 29(29):4157-69. PubMed ID: 20514018
[TBL] [Abstract] [Full Text] [Related]
18. A personalized approach to cancer treatment: how biomarkers can help.
Duffy MJ; Crown J
Clin Chem; 2008 Nov; 54(11):1770-9. PubMed ID: 18801934
[TBL] [Abstract] [Full Text] [Related]
19. A pai-1 (serpine1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group.
French D; Hamilton LH; Mattano LA; Sather HN; Devidas M; Nachman JB; Relling MV;
Blood; 2008 May; 111(9):4496-9. PubMed ID: 18285546
[TBL] [Abstract] [Full Text] [Related]
20. Favorable response of pediatric stem cell recipients to human protein C concentrate substitution for veno-occlusive disease.
Eber SW; Gungor T; Veldman A; Sykora K; Scherer F; Fischer D; Grigull L
Pediatr Transplant; 2007 Feb; 11(1):49-57. PubMed ID: 17239123
[TBL] [Abstract] [Full Text] [Related]
[Next]
